Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


All Eyes On US Patent And Trademark Board As ITC Approves Apple Watch Import Ban

Executive Summary

An import ban on Apple Watches has been put on hold as the US Patent and Trial and Appeal Board (PTAB) reviews AliveCor’s patent appeal.

The US International Trade Commission has issued a final ruling that Apple infringed on AliveCor Inc.’s patented electrocardiogram technology and banning the offending Apple Watches (series 4, 5, 6, 7 and 8) from being imported into the country.

However, the ban was placed on hold because an appeal in the case is still before the PTAB. The patent board sided with Apple last month, finding that all 30 of AliveCor’s claims were unpatentable. AliveCor appealed that ruling, and ITC has granted an Apple emergency motion arguing that the ban should be put on hold until the PTAB case is resolved. (Also see "Apple Vs. AliveCor: ECG Patent Battle Headed To Import Ban Decision" - Medtech Insight, 16 Dec, 2022.)

The Biden administration now has 60 days to choose to overturn the ban based on policy concerns. While Presidents have rarely vetoed import bans in the past, the Obama administration did veto a ban on Apple iPhones and iPads that were found to violate Samsung patents in 2013.

The administrative review period ends on February 12.

The ITC also set a fine of $2 per Apple Watch that is imported under the import ban, but this is also on hold pending the PTAB decision.

AliveCor filed suit against Apple in California Federal Court for “anticompetitive behavior,” AliveCor explained in a release. The trial is expected to begin in early 2024.

The ITC ruling reaffirms its earlier decision in June 2022 to side with AliveCor in the patent battle. (Also see "ITC Ruling Hands AliveCor Big Win Against Tech Giant" - Medtech Insight, 29 Jun, 2022.)

In 2017, AliveCor released KardiaBand, an ECG add-on for apple watches. When Apple released a new version of its watch with similar technologies, AliveCor stopped the sale of KadriaBand and sued Apple for patent infringement. (Also see "AliveCor Shows Off Apple Watch EKG Play, Launches Upgrades" - Medtech Insight, 16 Mar, 2016.)

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts